Glass House Brands (GLAS) Long-Term Investments (2020 - 2025)
Glass House Brands (GLAS) posted quarterly Long-Term Investments of $172000.0 for Q2 2025, down 92.36% year-over-year from $2.3 million in Q2 2024, and down 92.78% quarter-over-quarter from $2.4 million in Q1 2025.
Glass House Brands (GLAS) Long-Term Investments (2020 - 2025) Analysis & Trends
Glass House Brands (GLAS) has reported Long-Term Investments for 6 consecutive years, with $172000.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Long-Term Investments fell 92.36% year-over-year to $172000.0; the TTM figure through Jun 2025 stood at $172000.0 (down 92.36% YoY), while the FY2024 annual figure was $2.3 million, up 0.6% from the prior year.
- Long-Term Investments retreated to $172000.0 in Q2 2025 per GLAS's latest filing, from $2.4 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $8.9 million in Q1 2021 and bottomed at $172000.0 in Q2 2025.
- Historically, Long-Term Investments has averaged $3.9 million across 5 years, with a median of $2.3 million in 2024.
- Annual changes were most pronounced in 2024 — Long-Term Investments increased 18.3% — and 2025, when it tumbled 92.36%.
- Glass House Brands' Long-Term Investments stood at $7.2 million in 2021, then plunged by 41.0% to $4.2 million in 2022, then sank by 45.2% to $2.3 million in 2023, then gained by 0.6% to $2.3 million in 2024, then tumbled by 92.65% to $172000.0 in 2025.
- Business Quant data shows GLAS's Long-Term Investments at $172000.0 in Q2 2025, $2.4 million in Q1 2025, and $2.3 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 92.58 Mn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 63.23 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 1.14 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 60.00 Mn |
| 10 | Glass House Brands | 866.27 Mn | 847.71 Mn | 15.77 Mn | 14.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 172,000.00 |
| Mar 31, 2025 | 2.38 Mn |
| Dec 31, 2024 | 2.34 Mn |
| Sep 30, 2024 | 2.30 Mn |
| Jun 30, 2024 | 2.25 Mn |
| Mar 31, 2024 | 2.35 Mn |
| Dec 31, 2023 | 2.33 Mn |
| Sep 30, 2023 | 2.11 Mn |
| Jun 30, 2023 | 2.02 Mn |
| Mar 31, 2023 | 1.98 Mn |
| Dec 31, 2022 | 4.25 Mn |
| Sep 30, 2022 | 4.49 Mn |
| Jun 30, 2022 | 6.87 Mn |
| Mar 31, 2022 | 6.94 Mn |
| Dec 31, 2021 | 7.20 Mn |
| Sep 30, 2021 | 8.16 Mn |
| Mar 31, 2021 | 8.94 Mn |
| Dec 31, 2020 | 10.70 Mn |